The Science Behind the Female Libido Pill

INDICATION ADDYI (flibanserin) is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: A co-existing medical or psychiatric condition, The effects of a medication or other drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire.

• Some pink pills combine herbal extracts like ginseng or maca for effects.
• They are popular in wellness circles for enhancing intimacy and confidence.
• Research on pink pills' long-term safety is limited; caution is advised.
• Available through online stores, pharmacies, or clinics in some regions.

Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation, or partner.

ADDYI is not indicated to enhance sexual performance. Moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors sex power tablet Known hypersensitivity to ADDYI or any of its components.

• Pink pills are sometimes associated with the "pink economy" in sexual health.
• They are popular among women seeking discreet, quick solutions.
• Not all pink pills are evidence-based; some rely heavily on marketing claims.
• Consulting a healthcare professional is essential before starting any supplement.

Reactions, including anaphylaxis, reactions consistent with angioedema, pruritus, and urticaria have been reported. Hypotension and Syncope Due to an Interaction with Alcohol: See Boxed Warning for risks associated with alcohol consumption. After taking ADDYI at bedtime, advise patients to not use alcohol until the following day. Hypotension and Syncope with CYP3A4 Inhibitors: See Boxed Warning and Contraindication about use with moderate or strong cytochrome P450 3A4. Concomitant use of multiple weak CYP3A4 inhibitors that may include herbal supplements (e.g., ginkgo, resveratrol) or non-prescription drugs (e.g., cimetidine) could also lead to clinically relevant increases in flibanserin concentrations that may increase the risk of hypotension and syncope. Central Nervous System (CNS) Depression (e.g., Somnolence, Sedation): Can occur with ADDYI alone and is exacerbated by other CNS depressants.

Is Addyi effective?

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: A post hoc analysis. WARNING: HYPOTENSION AND SYNCOPE IN CERTAIN SETTINGS See full prescribing information for complete boxed warning. Use of ADDYI and alcohol together close in time increases the risk of severe hypotension and syncope. Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more standard alcoholic drinks that evening. Severe hypotension and syncope can occur when ADDYI is used with moderate or strong CYP3A4 inhibitors or in patients with hepatic impairment; therefore, ADDYI use in these settings is contraindicated. The risk of CNS depression is also increased if ADDYI is taken during waking hours. Patients should avoid activities requiring full alertness (e.g., operating machinery or driving) until at least six hours after each dose and until they know how ADDYI affects them. Hypotension and Syncope with ADDYI Alone: The use of ADDYI - without other concomitant medications known to cause hypotension or syncope - can cause hypotension and syncope.

The risk is increased if ADDYI is taken during waking hours or if higher than the recommend dose is taken.

Syncope and Hypotension in Patients with Hepatic Impairment: Any degree of hepatic impairment significantly increases flibanserin concentrations, which can lead to hypotension and syncope.

ADDYI is contraindicated in patients with hepatic impairment. Hypersensitivity Reactions: Reactions including anaphylaxis, reactions consistent with angioedema, pruritus, and urticaria have been reported with ADDYI.

When a drug became a movement

Eckert’s team went ahead and launched the largest clinical trial in women’s health history for an FDA filing — involving more than 13,000 participants. However, as revealed in the documentary, despite the data clearly demonstrating Addyi’s positive impact on women’s sexual desire, in 2013 the FDA turned down the application to take the drug to market. Moderate success and dangerous side effects were cited, including the patronizing notion that “a woman might take Addyi the night before and fall asleep the next morning while driving her kids to school.” Undeterred, Eckert and her team spent over US$1 million conducting a driving study that revealed enhanced reaction times among women taking Addyi. Eckert also created the Even the Score campaign that brought Sprout’s mission of sexual health equity for women into public conversations in a new and powerful way. Influential physicians came on board for medical credibility, and so did women who’d taken Addyi.

Drug Interactions

They protested, they supported Sprout and their local women’s health agencies, and they provided testimony when Eckert applied for FDA approval again. Their heartbreaking stories of divorce, self-doubt and soul-numbing frustration with being ignored or told their sexual lives are irrelevant are difficult to watch. In August 2015, Sprout Pharmaceuticals won by a vote of 18-6. Two days later, Eckert sold Addyi to Valeant Pharmaceuticals for mass distribution for $1 billion. Valeant, however, then raised the price and imposed restrictions on the drug’s sale, placing it beyond the reach of most women financially, and many physicians refused to prescribe it.

Related Stories

Spurred into action once again, Sprout Pharmaceuticals filed a lawsuit against Valeant. The case was dropped and Eckert bought Addyi back for $0 — a remarkable turnaround. The Pink Pill is a galvanizing film that exposes how medical sexism contributes to the dismissal of women’s sexuality. Low desire, especially in midlife, is a real condition worthy of scientific research and pharmaceutical development. Using a documentary film as the medium to tell this story is, as producer Julie Bristow said in an interview, “a very powerful way of getting people to engage.” It’s an emotionally compelling film, but it’s also educational. Immediately discontinue ADDYI and initiate appropriate treatment if hypersensitivity reaction occurs. Oral Contraceptives and Other Weak CYP3A4 Inhibitors: Increases flibanserin exposures and incidence of adverse reactions. Strong CYP2C19 Inhibitors: Increases flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression.

What challenges have you faced in bringing a pill for women in menopause to market?

Safety of flibanserin in women treated with antidepressants: A randomized, placebo-controlled study. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Neural basis of hypoactive sexual desire disorder in women: an event-related fmri study. Holstege G.

Contact Us

How the emotional motor system controls lovegra women the pelvic organs. Attitudinal survey of women living with low sexual desire. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): Results from a randomized withdrawal trial. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. CYP3A4 Inducers: Use of ADDYI not recommended, flibanserin concentrations substantially reduced Digoxin: Increases digoxin concentrations, which may lead to digoxin toxicity. Most common adverse reactions (ADDYI incidence ≥2% and higher than placebo) are dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. See Full Prescribing Information and Medication Guide, including Boxed Warning regarding hypotension and syncope in certain settings. Acquired HSDD refers to HSDD that develops in a patient who previously had no problem with sexual desire.

Why do you think sexual desire in women is not treated seriously by the medical community?

This is a central goal for Bristow, who said: “What I hope women take away from this, and men, is that men and women’s sexual health is dealt with completely differently and in the wider health-care system as well.” By combining scientific debate, personal testimony and political activism, The Pink Pill makes a persuasive case that women’s sexual health has long been treated as a medical afterthought — that changing this truth requires cultural progress too. The only FDA-approved pill proven safe and effective for Hypoactive Sexual Desire Disorder (HSDD) in BOTH premenopausal and postmenopausal women (<65). 70% of women want you to start the convo about sexual health.2 70% of women want you to start the convo about sexual health.2 The exact mechanism of action of Addyi is unknown. I testified at the FDA 10 years ago when Addyi was approved — a watershed moment that validated women’s sexual health with the first FDA approved option to treat women with frustrating low libido. In my practice, it opened conversations that had long been silenced and gave patients hope.

Related medical questions

“Addyi has helped me get my libido back. My sweet husband has been so patient with me for years now – I dreaded his advances – I can’t tell you how wonderful it has been to want sex again.” “When I heard about Addyi, I was premature ejaculation treatment curious if it would work for me. After only a few weeks on Addyi I’m already thinking about and wanting sex again!” “I used to dread going to bed with my husband, because I was never in the mood… he thought it was his fault. IQVIA Monthly Total Prescriptions Volume Data in the US. MEDICAL INFO: 844-746-5745 x 3 medicalaffairs@sproutpharma.com MEDICAL INFO: 844-746-5745 x 3 medicalaffairs@sproutpharma.com IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US.

Related support groups

Ryan KL, Arbuckle-Bernstein V, Smith G, Phillips J. Let’s Talk About Sex: A Survey of Patients’ Preferences When Addressing Sexual Health Concerns in a Family Medicine Residency Program Office. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. ADDYI is not indicated for use in men. Hypoactive Sexual Desire Disorder (HSDD), commonly called “decreased libido”, affects approximately 10% of the female population across all age groups, according to the International Society for Sexual Medicine.